Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05
Source: SeekingAlpha
2025-11-14 05:15:06 ET
More on Monopar Therapeutics
- Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted
- Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent
- Monopar Therapeutics announces pricing of $135M offering
- Monopar a new outperform at Oppenheimer on Wilson disease candidate
- Seeking Alpha’s Quant Rating on Monopar Therapeutics
Read the full article on Seeking Alpha
For further details see:
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05
Monopar Therapeutics Inc.
NASDAQ: MNPR
MNPR Trading
3.73% G/L:
$58.625 Last:
74,240 Volume:
$57.82 Open:
MNPR Latest News
March 02, 2026 08:00:00 am
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
November 13, 2025 08:00:00 am
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
MNPR Stock Data
$384,114,928
4,169,932
0.03%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmette
